From 07/07/2020 to 07/07/2020
The widely used TNM staging system is poorly predictive of response to adjuvant chemotherapy in Stage II and III colon cancer and there is a strong need for a better prognostic and predictive tool to personalize treatment decisions in colorectal cancer.
The World Health Organization (WHO) recently introduced immune response as an essential and desirable diagnostic criterion for CRC alongside standard histological parameters and Immunoscore® is the first consensus, standardized and commercially available test clinically validated for this assessment.
This webinar will focus on our latest data presented at ASCO 2020 and ESMO-GI 2020. First, prognostic performance on T4N0 colon cancer patients will be presented, showing that Immunoscore® identifies which patients have a lower risk of recurrence who might be spared adjuvant chemotherapy. Secondly, use of TNM-Immune (TNM-I) classification system to determine treatment benefit in selected patients will be discussed.
Jérôme Galon, Ph.D, Director, Inserm, Cordeliers Research Center, Paris, France
Graham Poage, Ph.D, Medical Science Director, HalioDx Inc.
Attendees of this webinar will learn: